ReviewNeuro-oncology2019
Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma.
Review in Neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
124 citing papers in PubMed, 1 synthesis or guideline pooled it, 194 citations in OpenAlex.
- Ocular oncology practice guidelines during COVID-19 pandemic-An expert consensus.Indian journal of ophthalmology · 2020Guideline
- A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART).Japanese journal of clinical oncology · 2026Trial
- IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma.Future oncology (London, England) · 2026Trial
- Phase II Trial of an Orelabrutinib-Based Combination Therapy in Newly Diagnosed Primary Central Nervous System Lymphoma.Blood and lymphatic cancer : targets and therapy · 2025Trial
- Long-term Outcomes in Primary CNS Lymphoma After R-MVP and High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplant.Neurology · 2023Trial
- Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma.Neurology · 2020Trial
- Prognostic Value of Subependymal Enhancement on Baseline MRI in Primary Central Nervous System Lymphoma.Cancers · 2026Article
- Dural Lymphomas Unmasked: A Narrative Review of Extra-Axial Mimics and a Pragmatic Diagnostic Decision Algorithm.Cancers · 2026Review
- Article
- Comparison of Fluorescent Probes for IDH-Wildtype Glioblastoma, Metastatic Brain Tumors, and PCNSL: A Biomechanical Perspective.International journal of molecular sciences · 2026Review
- Minimizing the risks of stereotactic brain biopsy in suspected central nervous system lymphoma: a retrospective database study.Journal of cancer research and clinical oncology · 2026Article
- Primary brainstem lymphoma: clinical characteristics, treatment methods, and prognostic factors of 56 patients.The oncologist · 2026Article
- The Regulation of Vasomotor and Cardiorespiratory Pulsations Is Disrupted in Primary Central Nervous System Lymphoma: A Case-Control fMRI Study.Human brain mapping · 2026Article
- Multiple primary central nervous system lymphoma in the ventricular system and interpeduncular cistern: A case report.Oncology letters · 2026Article
- Educational and regional differences in population-based incidence and survival of primary central nervous system lymphoma in Finland.BMC cancer · 2026Article
- Cumulative pre-chemoimmunotherapy dexamethasone dose is associated with adverse outcomes in primary central nervous system lymphoma.Frontiers in oncology · 2026Article
- Primary central nervous system T-cell lymphoma: a single-centre retrospective study and literature review.BMJ neurology open · 2026Article
- Orelabrutinib and rituximab regimen combined with intravitreal methotrexate for treatment of primary vitreoretinal lymphoma: a case report and literature review.Frontiers in oncology · 2026Article
- Article
- Elevated polyglutamylation and tau phosphorylation levels are associated with cognitive impairment at diagnosis in patients with primary central nervous system lymphoma.Alzheimer's research & therapy · 2025Article
64 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma that affects the brain parenchyma, spinal cord, eyes, and cerebrospinal fluid without evidence of systemic, non-CNS involvement. PCNSL is uncommon and only a few randomized trials have been completed in the first-line setting. Over the past decades, the prognosis of PCNSL has improved, mainly due to the introduction and widespread use of high-dose methotrexate, which is now the backbone of all first-line treatment polychemotherapy regimens. Despite this progress, durable remission is recorded in only 50% of patients, and therapy can be associated with significant late neurotoxicity. Here, we overview the epidemiology, clinical presentation, staging evaluation, prognosis, and current up-to-date treatment of immunocompetent PCNSL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.